Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Med ; 2010: 459543, 2010.
Article in English | MEDLINE | ID: mdl-21209734

ABSTRACT

We present a 5-year-old boy who had the complaint of swelling and pain on the right vaccine shot and right axillary areas. The right axillary area was diagnosed as reactive lymphadenitis, which we believe is a rare local side effect of the swine flu vaccine. The key message to take away from this case is that the patient had lymphadenitis as a local side effect of the swine flu vaccine. Lymphadenitis should be reported as a possible local side effect of the swine flu vaccine.

2.
Hepatogastroenterology ; 49(45): 783-7, 2002.
Article in English | MEDLINE | ID: mdl-12063990

ABSTRACT

BACKGROUND/AIMS: Several drugs have been used to reduce portal hypertension. Losartan constitutes arteriolar and venous vasodilation by inhibiting the effects of the increased angiotensin II in cirrhotic patients. In this study, we analyzed the effects of losartan, when used alone and when combined with somatostatin, on portal and renal hemodynamics. METHODOLOGY: Seventeen patients with cirrhosis were enrolled. During the study, the patients were administered 250 micrograms of somatostatin i.v. bolus and subsequent infusion at a rate of 250 micrograms/hr for 2 hours on the second day; 25 mg losartan orally on the fourth day; and losartan and somatostatin together, in the same doses as the second and the fourth day, were given on the sixth day. RESULTS: The portal flow volume and the velocity that were measured after the administration of somatostatin, losartan and the combination of each drug, were found to be increased when compared with the initial values (P < 0.001). Additionally, the creatinine clearances were increased and statistically significant with somatostatin. CONCLUSIONS: Considering its low cost, easy usability, long lasting effect, we suggest that losartan can be used as an alternative treatment in the clinical conditions where portal pressure should be reduced and can be combined with somatostatin without any significant adverse effects.


Subject(s)
Antihypertensive Agents/pharmacology , Hormones/pharmacology , Kidney/physiopathology , Liver Cirrhosis/drug therapy , Liver Cirrhosis/physiopathology , Losartan/pharmacology , Portal System/physiopathology , Somatostatin/pharmacology , Adult , Drug Therapy, Combination , Female , Hemodynamics/drug effects , Humans , Kidney/drug effects , Male , Middle Aged , Portal System/drug effects , Regional Blood Flow/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...